CA3034694A1 - Compounds for treating diseases associated with a mitochondrial dysfonction - Google Patents
Compounds for treating diseases associated with a mitochondrial dysfonction Download PDFInfo
- Publication number
- CA3034694A1 CA3034694A1 CA3034694A CA3034694A CA3034694A1 CA 3034694 A1 CA3034694 A1 CA 3034694A1 CA 3034694 A CA3034694 A CA 3034694A CA 3034694 A CA3034694 A CA 3034694A CA 3034694 A1 CA3034694 A1 CA 3034694A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- carbon atoms
- compound
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0 | 2016-08-30 | ||
| EP16306094.0A EP3290039B1 (en) | 2016-08-30 | 2016-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
| PCT/EP2017/071812 WO2018041919A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3034694A1 true CA3034694A1 (en) | 2018-03-08 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034694A Pending CA3034694A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (enExample) |
| EP (2) | EP3290039B1 (enExample) |
| JP (1) | JP7065854B2 (enExample) |
| KR (1) | KR20200011927A (enExample) |
| CN (1) | CN110035758B (enExample) |
| AU (1) | AU2017317651B2 (enExample) |
| BR (1) | BR112019004236A2 (enExample) |
| CA (1) | CA3034694A1 (enExample) |
| ES (1) | ES2800917T3 (enExample) |
| MA (1) | MA46099A (enExample) |
| MX (1) | MX394782B (enExample) |
| RU (1) | RU2019108824A (enExample) |
| SG (1) | SG11201901689YA (enExample) |
| WO (1) | WO2018041919A1 (enExample) |
| ZA (1) | ZA201900997B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
| JP2021517124A (ja) * | 2018-03-07 | 2021-07-15 | エーエムエーバイオティクス | アルツハイマー病を治療するための化合物 |
| US20220096574A1 (en) * | 2019-01-29 | 2022-03-31 | Holobiome, Inc. | Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis |
| EP4028014A1 (en) * | 2019-09-12 | 2022-07-20 | Stellate Therapeutics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
| CN116850191A (zh) * | 2023-06-16 | 2023-10-10 | 山东大学齐鲁医院 | 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用 |
| WO2026057085A1 (zh) * | 2024-09-15 | 2026-03-19 | 澳门科技大学 | Queuine在抗衰老中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| JPH11506426A (ja) * | 1995-04-25 | 1999-06-08 | オリディグム コーポレイション | 代謝経路のｓ−アデノシルメチオニン調節ならびに診断および治療におけるその使用 |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417163D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
-
2016
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/en active Active
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
-
2017
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko not_active Abandoned
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/en not_active Ceased
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/en not_active Withdrawn
- 2017-08-30 CA CA3034694A patent/CA3034694A1/en active Pending
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 MX MX2019002369A patent/MX394782B/es unknown
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004236A2 (pt) | 2019-05-28 |
| JP2019526634A (ja) | 2019-09-19 |
| EP3290039A1 (en) | 2018-03-07 |
| AU2017317651B2 (en) | 2022-12-15 |
| SG11201901689YA (en) | 2019-03-28 |
| US20210046056A1 (en) | 2021-02-18 |
| CN110035758A (zh) | 2019-07-19 |
| US10857135B2 (en) | 2020-12-08 |
| MA46099A (fr) | 2019-07-10 |
| MX394782B (es) | 2025-03-24 |
| ZA201900997B (en) | 2020-05-27 |
| ES2800917T3 (es) | 2021-01-05 |
| US11684611B2 (en) | 2023-06-27 |
| RU2019108824A (ru) | 2020-10-01 |
| MX2019002369A (es) | 2019-11-07 |
| JP7065854B2 (ja) | 2022-05-12 |
| KR20200011927A (ko) | 2020-02-04 |
| EP3506903A1 (en) | 2019-07-10 |
| EP3290039B1 (en) | 2020-03-25 |
| CN110035758B (zh) | 2023-06-16 |
| RU2019108824A3 (enExample) | 2020-12-31 |
| WO2018041919A1 (en) | 2018-03-08 |
| AU2017317651A1 (en) | 2019-03-07 |
| US20190224174A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11684611B2 (en) | Compounds for treating diseases associated with a mitochondrial dysfunction | |
| ES2408785T3 (es) | Nuevos enfoques terapéuticos para el tratamiento de CMT y trastornos relacionados | |
| JP2022033788A (ja) | ソベチロム誘導体 | |
| Kwon et al. | Korean Red Ginseng and Rb1 facilitate remyelination after cuprizone diet-induced demyelination | |
| WO2021048431A1 (en) | Compounds for treating ataxia | |
| Zhang et al. | Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets | |
| US12358867B1 (en) | Peptoid-based inhibitors of the protein arginine methyltransferase (PRMT) family | |
| CA3093212A1 (en) | Compounds for treating alzheimer's disease | |
| US20230040247A1 (en) | Compounds for treating neurodegenerative diseases | |
| JP7630540B2 (ja) | 神経保護ペプチド | |
| KR20010102463A (ko) | 신경퇴행성 질환 치료용 의약을 제조하기 위한 티아넵틴의 용도 | |
| US20190031701A1 (en) | Dicaffeoyl Spermidine Cyclized Derivatives And Use Thereof | |
| Zhao et al. | Extracellular vesicle-based bumetanide delivery alleviates depression-like behaviors of male mice by restoring chloride homeostasis | |
| KR20040012396A (ko) | 뇌신경성장인자 증강작용을 갖는 백강잠 추출물 및 이의활성성분을 함유하는 약학적 제제 | |
| JP7781422B2 (ja) | Ｃｂ１受容体アゴニストの副作用を軽減するペプチド化合物 | |
| Fisher et al. | Stimulatory effect of amphotericin B methyl ester on the growth of LM and Vero cells | |
| Saidi et al. | The Effect of Sitagliptin and Liraglutide on the Lipopolysaccharide Rat Model of Parkinson’s Disease | |
| KR100487113B1 (ko) | 백강잠 101ａ로부터 분리, 정제한 뇌신경성장 촉진물질(4ｅ, 6ｅ, 2ｓ,3ｒ)-2-ｎ-도코사노일-4,6-테트라데카스핀가디에닌 | |
| KR20040012397A (ko) | 백강잠 101ａ로부터 분리, 정제한 뇌신경성장 촉진물질(4ｅ, 6ｅ, 2ｓ,3ｒ)-2-ｎ-아이코사노일-4,6-테트라데카스핀게닌 | |
| EP3359177A1 (en) | Use of a withania extract for the treatment of demyelinating deseases | |
| CN103374057A (zh) | 一种对甘氨酸转运子具有抑制活性的新化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220705 |